What is the current price and short-term technical view for 2228.HK stock?

2228.HK stock trades at **HK$11.26** pre-market on 24 Feb 2026. RSI is **43.80** and MACD is slightly negative, so momentum is neutral. Support is near **HK$11.11** (50-day) and **HK$9.09** (200-day), with resistance at **HK$13.19** and **HK$15.12**.

How does XtalPi’s valuation look for 2228.HK stock?

Valuation mixes value and premium signals: reported **PE 10.71** and EPS **1.05**, but price-to-sales is **62.82** and price-to-book is **5.35**, indicating high revenue multiple versus current profitability. Strong R&D spend explains some premium.

What are the main catalysts and risks for 2228.HK stock?

Catalysts include partnership announcements, milestone payments and commercial adoption of AI lab automation. Key risks are long receivables (**268.35 days**), negative operating margins, execution on partnerships and regulatory exposure in healthcare.

What price targets and forecasts exist for 2228.HK stock from Meyka AI?

Meyka AI's forecast model projects yearly **HK$10.73** (implied **-4.77%** vs **HK$11.26**) and quarterly **HK$13.19** (+**17.14%**). Suggested targets: conservative **HK$9.00**, base **HK$13.19**, bull **HK$23.91**. Forecasts are model-based and not guarantees.

HK Stocks

HK$11.26 pre-market 24 Feb 2026: 2228.HK XtalPi (HKSE) AI growth signals

ByDanny Kontos February 23, 2026

XtalPi (2228.HK) trades at HK$11.26 pre-market on 24 Feb 2026, making the stock a live play on AI-driven drug discovery. The 2228.HK stock shows mixed signals: a PE of 10.71 and EPS of 1.05 contrast with high price-to-sales and heavy R&D spend. Market participants will watch quarterly channels and partnership news for fresh catalysts. We use price, technicals and Meyka AI models to frame near-term risk and realistic upside.